NewStem For Profit
NewStem is a Jerusalem-based biotech with a novel precision-medicine technology that can increase chemotherapy's effectiveness. NewStem is a spinoff of Yissum, The Technology Transfer Company of The Hebrew University. NewStem's technology can predict patients' resistance to chemotherapy allowing for better, targeted cancer treatments and the potential to reduce resistance to chemotherapy.
Total Funding:
$4M
Headquarters:
Jerusalem, Yerushalayim, Israel
Funding Status:
Seed
Employee Number:
11-50
Last Funding Type:
Seed
Technology:
Biomarker panels
Investors Number:
1
Founded Date:
2016-09-01
Industry:
Clinical Data Management